Related Experiment Video

Updated: Feb 6, 2026

Pyrosequencing: A Simple Method for Accurate Genotyping
13:06

Pyrosequencing: A Simple Method for Accurate Genotyping

Published on: January 8, 2008

28.1K

Distribution of hepatitis C genotypes in Uttar Pradesh, India; rare genotype 4 detected

Shantanu Prakash1, Suruchi Shukla1, Vangala Ramakrishna1

  • 1Virology Research and Diagnostic Laboratory, Department of Microbiology, King George's Medical University, Lucknow, India.

Journal of Medical Virology
|August 8, 2018
PubMed

Insights

Hepatitis C virus (HCV) genotype 3a and 1a are most common in Uttar Pradesh, India. This study analyzed 404 HCV cases, finding significant genotypic variability, particularly within HCV GT3.

Area of Science:

  • Virology
  • Hepatology
  • Genetics

Background:

  • Hepatitis C virus (HCV) infection affects 150-170 million globally, with India having a 1% prevalence.
  • HCV genotype 3 (GT3) is predominant in India, followed by GT1.
  • Understanding regional HCV genotype distribution is crucial for treatment strategies.

Purpose of the Study:

  • To determine the prevalent hepatitis C virus genotypes and subtypes in Uttar Pradesh, North India.
  • To analyze the genetic diversity and phylogenetic relationships of circulating HCV strains.

Main Methods:

  • Retrospective observational analysis of 404 HCV RNA positive cases from September 2014 to April 2017.
  • Sanger sequencing of the core region for HCV genotyping of all 404 strains.
  • Phylogenetic analysis of 179 HCV strains with high-quality sequencing data.

Main Results:

  • Hepatitis C virus genotype 3a (68.07%) and 1a (25%) were the most prevalent genotypes.
  • HCV GT3 exhibited high genotypic variability, with GT3a being the most common subtype.
  • HCV GTs 2, 5, and 6 were not detected; GT1b, GT1c, GT3b, GT3g, GT3i, and GT4a were found in lower proportions.

Conclusions:

  • HCV GTs 3a and 1a are the predominant circulating genotypes in Uttar Pradesh, India.
  • The findings highlight the specific genotypic landscape of HCV in North India.
  • Phylogenetic analysis confirmed the relation of local strains to previously reported Indian strains.
Abstract

Keywords:
bioinformaticsgenetic variationgenotypehepatitis C virus

More Related Videos

Frequency and Distribution of Crossovers in Caenorhabditis elegans Meiosis by SNP Genotyping using Real-time PCR06:18

Frequency and Distribution of Crossovers in Caenorhabditis elegans Meiosis by SNP Genotyping using Real-time PCR

Published on: July 11, 2025

886
Genotyping of Sea Anemone during Early Development07:04

Genotyping of Sea Anemone during Early Development

Published on: May 13, 2019

6.1K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
Drug Distribution: Volume of Distribution01:25

Drug Distribution: Volume of Distribution

The volume of distribution refers to the theoretical volume necessary to contain the entire amount of an administered drug at the same concentration observed in the blood plasma. The body's intracellular fluid compartment, which makes up two-thirds of the total body water, is contrasted with the extracellular fluid compartment—comprising plasma and interstitial fluid—that accounts for one-third. The volume of distribution can vary depending on the characteristics of the drug.
7.5K
F Distribution01:19

F Distribution

The F distribution was named after Sir Ronald Fisher, an English statistician. The F statistic is a ratio (a fraction) with two sets of degrees of freedom; one for the numerator and one for the denominator. The F distribution is derived from the Student's t distribution. The values of the F distribution are squares of the corresponding values of the t distribution. One-Way ANOVA expands the t test for comparing more than two groups. The scope of that derivation is beyond the level of this...
10.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
685